Felipe Lombó has a PhD in Biology from the University of Oviedo (1998) and is currently Full Professor at this university. He has carried out his research activity at the Ruhr-Universität Bochum (Germany), University of Oviedo and Stanford University (USA), with shorter stays at Georg-August Universität Göttingen (Germany), Analyticon AG (Germany), Universidade de São Paulo (Brazil) and The University of Tokyo (Japan).

He has developed ultra-rapid pathogen detection methods. His main research is the development of new antitumor drugs (of bacterial or plant origin), antibiotics (to prevent biofilm infections) and nutraceuticals (flavonoids, stilbenes, prebiotic polysaccharides) in genetically improved and industrially scalable bacterial factories (Streptomyces) and from microalgae. His research includes metagenomic studies on digestive microbiota, analyzing changes associated with the intake of nutraceuticals and their relationship with the prevention of colon carcinoma, ulcerative colitis and metabolic syndrome.

He leads the BIONUC (Biotechnology of Nutraceuticals and Bioactive Compounds) research group, which is part of the IUOPA (University Institute of Oncology of the Principality of Asturias) and ISPA (Health Research Institute of the Principality of Asturias-Severo Ochoa Center of Excellence). He has directed 8 PhD thesis. He is the author of 12 patents and more than 90 research articles in international journals (h-index: 35).